RT Journal Article
T1 Antibody Responses to Helicobacter pylori and Risk of Developing Colorectal Cancer in a European Cohort.
A1 Butt, Julia
A1 Jenab, Mazda
A1 Pawlita, Michael
A1 Tjønneland, Anne
A1 Kyrø, Cecilie
A1 Boutron-Ruault, Marie-Christine
A1 Carbonnel, Franck
A1 Dong, Catherine
A1 Kaaks, Rudolf
A1 Kühn, Tilman
A1 Boeing, Heiner
A1 Schulze, Matthias B
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 La Vecchia, Carlo
A1 Palli, Domenico
A1 Agnoli, Claudia
A1 Tumino, Rosario
A1 Sacerdote, Carlotta
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, Bas
A1 Vermeulen, Roel
A1 Gram, Inger T
A1 Weiderpass, Elisabete
A1 Borch, Kristin Benjaminsen
A1 Quirós, Jose Ramón
A1 Agudo, Antonio
A1 Rodríguez-Barranco, Miguel
A1 Santiuste, Carmen
A1 Ardanaz, Eva
A1 Van Guelpen, Bethany
A1 Harlid, Sophia
A1 Imaz, Liher
A1 Perez-Cornago, Aurora
A1 Gunter, Marc J
A1 Zouiouich, Semi
A1 Park, Jin Young
A1 Riboli, Elio
A1 Cross, Amanda J
A1 Heath, Alicia K
A1 Waterboer, Tim
A1 Hughes, David J
AB While Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer development. However, prospective studies addressing H. pylori and colorectal cancer are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in prediagnostic serum samples from 485 colorectal cancer cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific seropositivity with odds of developing colorectal cancer. Fifty-one percent of colorectal cancer cases were H. pylori seropositive compared with 44% of controls, resulting in an OR of 1.36 (95% CI, 1.00-1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by seropositivity to Helicobacter cysteine-rich protein C (HcpC; OR: 1.66; 95% CI, 1.19-2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34; 95% CI, 0.99-1.82), the latter being nonstatistically significant only in the fully adjusted model. In this prospective multicenter European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing colorectal cancer. Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease colorectal cancer incidence.
PB American  Association for Cancer Research
YR 2020
FD 2020-04-21
LK http://hdl.handle.net/10668/15430
UL http://hdl.handle.net/10668/15430
LA en
NO Butt J, Jenab M, Pawlita M, Tjønneland A, Kyrø C, Boutron-Ruault MC, et al. Antibody Responses to Helicobacter pylori and Risk of Developing Colorectal Cancer in a European Cohort. Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1475-1481.
NO This work was supported by The Health Research Board of Ireland project grant(grant number HRB-ILP-021, to D.J. Hughes). The authors thank Ute Koch, MonikaOppenl€ander, and Claudia Brandel for excellent technical assistance with theserologic measurements. The coordination of EPIC is financially supported by theEuropean Commission (DG-SANCO) and the International Agency for Research onCancer. The national cohorts are supported by the Danish Cancer Society (Denmark);Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l’EducationNationale, and Institut National de la Sante et de la Recherche Medicale (INSERM,France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and FederalMinistry of Education and Research (Germany); the Hellenic Health Foundation(Greece); the Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, AssociazioneItaliana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy);Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands CancerRegistry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (ZorgOnderzoek Nederland), World Cancer Research Fund (WCRF), and StatisticsNetherlands (the Netherlands); Nordic Centre of Excellence programme on Food,Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada,PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, BasqueCountry, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain;Swedish Cancer Society, Swedish Scientific Council, and County Councils of Ska neand V€asterbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford) and Medical Research Council [1000143 to EPIC-Norfolk,MR/M012190/1 to EPIC-Oxford (UK)].
DS RISalud
RD Apr 18, 2025